Condition: DLL3-expressing Tumors · Advanced Tumors · Sponsor: Jonsson Comprehensive Cancer Center
This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.
This description comes directly from the study's public registry record.
CRU Hotline · 888-798-0719 · JGGutierrez@mednet.ucla.edu
CRU Direct line · 310-206-2632
Always discuss trial participation with your own doctor first.
| UC Davis Comprehensive Cancer Center | Davis, California, United States | Recruiting |
| UCI Health Chao Family Comprehensive Cancer Center | Irvine, California, United States | Recruiting |
| University of California at Los Angeles | Los Angeles, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | San Diego, California, United States | Recruiting |
| University of California at San Francisco | San Francisco, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06788938